Serum bone gla-protein in osteoporosis treated with 1α-hydroxyvitamin D3 for more than five years

Eiji Itoi, Yuichiro Yamada, Minoru Sakurai, Kazutoshi Mizunashi, Kozo Satoh, Fumio Kasama

Research output: Contribution to journalArticle

Abstract

It has been reported that 1,25-dihydroxyvitamin D3 increases serum bone Gla-protein (BGP) in a short period in osteoporotic patients as well as in normal subjects. There have been, however, no reports on serum BGP in osteoporotic patients under long term treatment with 1α-hydroxyvitamin D3. We measured serum BGP in 11 osteoporotic women treated with 1α-hydroxyvitamin D3 and calcium for 5-12 years, 8.4 years on average. Bone mineral density of distal radius was assessed by single photon absorptiometry. Other biochemical parameters such as serum alkaline phosphatase, fasting urinary hydroxyproline/creatinine and calcium/creatinine were also measured. Serum BGP levels were 6.25±0.36ng/ml (mean±S.E.), being all within the normal range (6.2±3.86ng/ml). We found no significant correlation between serum BGP and other biochemical parameters. Significant correlation was found neither between serum BGP and period of treatment nor between serum BGP and bone mineral density. Our result that serum BGP is within the normal range in osteoporotic patients whose bone mineral density has been maintained by long-term treatment suggests the normal bone turnover in these patients.

Original languageEnglish
Pages (from-to)37-41
Number of pages5
JournalJournal of Bone and Mineral Metabolism
Volume7
Issue number1
DOIs
Publication statusPublished - 1989 Mar 1

Keywords

  • 1α-hydroxyvitamin D
  • bone Gla-protein (BGP)
  • bone mineral density
  • osteoporosis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine
  • Endocrinology

Fingerprint Dive into the research topics of 'Serum bone gla-protein in osteoporosis treated with 1α-hydroxyvitamin D<sub>3</sub> for more than five years'. Together they form a unique fingerprint.

  • Cite this